Human Papillomavirus Recombinant Vaccine nonavalent: all 63 studies that test it

Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• ESCUDDO Long Term Follow UpEnrolling by invitationNCT07706673Phase 4
• Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV VaccinationRecruitingNCT07407569Phase 2
• Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*Not yet recruitingNCT07339163Phase 1/2
• Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPVNot yet recruitingNCT07303751Phase 2
• The Mother-Daughter Project: Merck-4Not yet recruitingNCT07240220Not applicable
• Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female StudentsRecruitingNCT07156084Phase 4
• HPV Vaccine Reduced DoseRecruitingNCT06799494Phase 4
• Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus ExposureNot yet recruitingNCT06681636Phase 2
• Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical LesionsRecruitingNCT06658405Phase 2
• Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIVRecruitingNCT06624839Phase 2
• Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in RwandaNot yet recruitingNCT06536855Phase 4
• Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSILRecruitingNCT06052696Phase 4
• Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous WartsRecruitingNCT05625633Phase 2/3
• A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIVRecruitingNCT05495906Phase 4
• Immunogenicity of 9-valent HPV VaccineRecruitingNCT05439083Phase 4
• Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIVRecruitingNCT05266898Phase 4
• Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in SwedenRecruitingNCT04910802Phase 4
• Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 YearsRecruitingNCT04895020Phase 3
• HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSILNot yet recruitingNCT03947775Phase 2
• Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9Not yet recruitingNCT03848039Phase 3
• Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)CompletedNCT05119855Phase 3Results posted
• Assessing Durable Antibody Response to HPV VaccinationCompletedNCT05031078Phase 4Results posted
• Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)CompletedNCT04772534Phase 3Results posted
• HPV Vaccination Study in Postpartum WomenCompletedNCT04274153Phase 4Results posted
• Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)CompletedNCT03546842Phase 3Results posted
• Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised PatientsCompletedNCT03525210Phase 3Results posted
• Postpartum HPV VaccinationCompletedNCT03451071Phase 4Results posted
• HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal LesionsTerminatedNCT03051516Phase 4Results posted
• Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant RecipientsActive, not recruitingNCT03036930Phase 2Results posted
• Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV VaccineCompletedNCT02968420Phase 4Results posted
• Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)CompletedNCT02864147Phase 2Results posted
• Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy ParticipantsActive, not recruitingNCT02568566Phase 2Results posted
• Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) StudyCompletedNCT01824537Phase 4Results posted
• Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)CompletedNCT01651949Phase 3Results posted
• Intralesional Gardasil-9 for the Treatment of Recalcitrant WartsActive, not recruitingNCT07806617Phase 2
• Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 YearsActive, not recruitingNCT07281677Phase 4
• A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesActive, not recruitingNCT06866574Phase 3
• Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.Active, not recruitingNCT06436274Phase 4
• A Cervical Cancer Prevention Program in KenyaActive, not recruitingNCT06411938Not applicable
• Immunogenicity of HPV Vaccine in Transplant Recipients.Active, not recruitingNCT05557370Phase 4
• V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)Active, not recruitingNCT05450705Phase 3
• Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years OldActive, not recruitingNCT05329961Early Phase 1
• Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)Active, not recruitingNCT05314023Phase 3
• Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)Active, not recruitingNCT05285826Phase 3
• Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO TrialActive, not recruitingNCT05237947Phase 4
• A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 YearsStatus unknownNCT05060484Phase 2
• HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in EswatiniCompletedNCT04982614Phase 4
• Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)Active, not recruitingNCT04708041Phase 3
• Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCompletedNCT04425291Phase 3
• 9-valent HPV Vaccine in Postpartum WomenStatus unknownNCT04311528Phase 4
• Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive WomenActive, not recruitingNCT04270773Phase 4
• Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO TrialCompletedNCT04265950Phase 4
• An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination RegimenActive, not recruitingNCT04206813Phase 4
• Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)Active, not recruitingNCT04199689Phase 3
• HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine TrialStatus unknownNCT03832049Phase 3
• A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017CompletedNCT03626467Phase 4
• Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell LymphocytopeniaActive, not recruitingNCT03519464Phase 2
• Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9CompletedNCT03431246Phase 3
• Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic VaccinationStatus unknownNCT03350698Phase 4
• HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPVCompletedNCT03284866Phase 3
• Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO StudyActive, not recruitingNCT03180034Phase 4
• Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03023631Phase 4
• A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian GirlsActive, not recruitingNCT02834637Phase 3

← Human Papillomavirus Recombinant Vaccine nonavalent overview